AU2016303662A1 - Bacteria engineered to treat disorders involving propionate catabolism - Google Patents

Bacteria engineered to treat disorders involving propionate catabolism Download PDF

Info

Publication number
AU2016303662A1
AU2016303662A1 AU2016303662A AU2016303662A AU2016303662A1 AU 2016303662 A1 AU2016303662 A1 AU 2016303662A1 AU 2016303662 A AU2016303662 A AU 2016303662A AU 2016303662 A AU2016303662 A AU 2016303662A AU 2016303662 A1 AU2016303662 A1 AU 2016303662A1
Authority
AU
Australia
Prior art keywords
gene
propionate
pct
bacterium
encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016303662A
Other languages
English (en)
Inventor
Dean Falb
Vincent ISABELLA
Jonathan Kotula
Paul Miller
Yves Millet
Alex TUCKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Operating Co Inc
Original Assignee
Synlogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/032565 external-priority patent/WO2016183532A1/en
Priority claimed from PCT/US2016/037098 external-priority patent/WO2016201380A1/en
Application filed by Synlogic Operating Co Inc filed Critical Synlogic Operating Co Inc
Publication of AU2016303662A1 publication Critical patent/AU2016303662A1/en
Assigned to SYNLOGIC OPERATING COMPANY, INC. reassignment SYNLOGIC OPERATING COMPANY, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: SYNLOGIC, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2016303662A 2015-07-31 2016-07-29 Bacteria engineered to treat disorders involving propionate catabolism Abandoned AU2016303662A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562199445P 2015-07-31 2015-07-31
US62/199,445 2015-07-31
US201662336338P 2016-05-13 2016-05-13
PCT/US2016/032565 WO2016183532A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to treat a disease or disorder
AUPCT/US2016/032565 2016-05-13
US62/336,338 2016-05-13
US201662341320P 2016-05-25 2016-05-25
US62/341,320 2016-05-25
AUPCT/US2016/037098 2016-06-10
PCT/US2016/037098 WO2016201380A1 (en) 2015-06-10 2016-06-10 Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
PCT/US2016/044922 WO2017023818A1 (en) 2015-07-31 2016-07-29 Bacteria engineered to treat disorders involving propionate catabolism

Publications (1)

Publication Number Publication Date
AU2016303662A1 true AU2016303662A1 (en) 2018-02-22

Family

ID=57944027

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016303662A Abandoned AU2016303662A1 (en) 2015-07-31 2016-07-29 Bacteria engineered to treat disorders involving propionate catabolism

Country Status (5)

Country Link
EP (1) EP3328988A1 (https=)
JP (1) JP2018521674A (https=)
AU (1) AU2016303662A1 (https=)
CA (1) CA2996535A1 (https=)
WO (1) WO2017023818A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018379996A1 (en) * 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
CA3142608A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
CN112143689B (zh) * 2019-06-28 2023-01-03 中国科学院微生物研究所 重组恶臭假单胞菌株的构建及其在转化苏氨酸合成丙酸中的应用
WO2021137937A2 (en) * 2019-11-05 2021-07-08 The Trustees Of Columbia University In The City Of New York Engineered bacteria containing biosensors for precision targeting and containment
AU2020394993A1 (en) 2019-12-02 2022-06-09 Astellas Pharma Inc. Ny-eso-1-containing artificial adjuvant vector cell for use in treatment of cancer
EP4090773A2 (en) * 2020-01-17 2022-11-23 Université catholique de Louvain Genetically modified bacterium with altered envelop integrity and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
AU3108400A (en) 1998-12-02 2000-06-19 Trustees Of Boston University Gene networks for control of gene expression
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
CA2846804A1 (en) * 2011-08-26 2013-03-07 Microbiota Diagnostics, Llc Methods for diagnosing and treating cardiac defects
WO2014066945A1 (en) * 2012-11-01 2014-05-08 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-modified probiotic for treatment of phenylketonuria
JP6283040B2 (ja) 2013-03-07 2018-02-21 ザ ジェネラル ホスピタル コーポレイション 細菌によるポリペプチド送達のための組成物および方法

Also Published As

Publication number Publication date
EP3328988A1 (en) 2018-06-06
CA2996535A1 (en) 2017-02-09
WO2017023818A1 (en) 2017-02-09
JP2018521674A (ja) 2018-08-09

Similar Documents

Publication Publication Date Title
US12409195B2 (en) Bacteria engineered to reduce hyperphenylalaninemia
US11845964B2 (en) Bacteria engineered to treat diseases associated with hyperammonemia
US20220233609A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
EP3307870B1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
US20170216370A1 (en) Bacteria engineered to treat disorders involving propionate catabolism
US20230092431A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
JP2018523978A (ja) 高アンモニア血症に関連する疾患を治療するために操作された細菌
WO2017123592A1 (en) Bacteria engineered to treat disorders associated with bile salts
AU2016303662A1 (en) Bacteria engineered to treat disorders involving propionate catabolism
WO2017075485A1 (en) Bacteria engineered to treat disorders in which trimethylamine (tma) is detrimental
US20220168362A1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SYNLOGIC OPERATING COMPANY, INC.

Free format text: FORMER NAME(S): SYNLOGIC, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application